Uncategorized

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
February 22nd, 2023
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
February 22nd, 2023
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
February 21st, 2023
PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RESUMED DOSING
November 16th, 2022
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
November 3rd, 2022
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
October 27th, 2022
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
October 12th, 2022
PFIZER AND SANGAMO THERAPEUTICS ANNOUNCE PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RE-OPENED RECRUITMENT
September 22nd, 2022
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
August 30th, 2022
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
August 4th, 2022